Ashley Barnes

Ashley has latterly spent the last 4 Years at Censo Biotechnologies where as the Chief Scientific Officer he lead the strategy and scientific development of new and novel induced pluripotent stem cells. Coupled to this was the development of robust disease relevant assays including co-culture models for neuroscience and inflammation. for contract research for both Biotech and Pharma. Ashley has extensive experience in the pharma industry having been at GlaxoSmithKline for 25 years in leading teams in Neuroscience, Respiratory and Immunology disease areas for numerous drug discovery programme with technical competencies including molecular biology, gene editing, pharmacology, cell scale -up functional assay development .